Is genetic testing coming of age in advanced prostate cancer?

BJU InternationalEarly View Comment Is genetic testing coming of age in advanced prostate cancer? Kenneth Chen, Corresponding Author Kenneth Chen [email protected] Department of Urology, Singapore General Hospital, Singapore, Singapore Correspondence: Kenneth Chen, 20 College Road, Academia Level 5, Department of Urology, Singapore General Hospital, Singapore 169856, Singapore. e-mail: [email protected]Search for more papers by this authorSean Ong, Sean Ong orcid.org/0000-0003-1117-2409 Royal Melbourne Hospital Clinical School, University of Melbourne, Melbourne, Victoria, Australia EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Victoria, AustraliaSearch for more papers by this authorKandarpa Vasundhara, Kandarpa Vasundhara orcid.org/0000-0002-7684-8169 Department of Urology, Singapore General Hospital, Singapore, SingaporeSearch for more papers by this authorChow Kit Mun, Chow Kit Mun Department of Urology, Singapore General Hospital, Singapore, SingaporeSearch for more papers by this authorIsabella Williams, Isabella Williams orcid.org/0000-0002-4149-468X Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaSearch for more papers by this authorRavindran Kanesvaran, Ravindran Kanesvaran Division of Medical Oncology, National Cancer Centre Singapore, Singapore, SingaporeSearch for more papers by this authorJohn Yuen Shyi Peng, John Yuen Shyi Peng Department of Urology, Singapore General Hospital, Singapore, SingaporeSearch for more papers by this authorArun A. Azad, Arun A. Azad orcid.org/0000-0001-7350-5622 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorNathan Lawrentschuk, Nathan Lawrentschuk orcid.org/0000-0001-8553-5618 Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Victoria, Australia Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaSearch for more papers by this author Kenneth Chen, Corresponding Author Kenneth Chen [email protected] Department of Urology, Singapore General Hospital, Singapore, Singapore Correspondence: Kenneth Chen, 20 College Road, Academia Level 5, Department of Urology, Singapore General Hospital, Singapore 169856, Singapore. e-mail: [email protected]Search for more papers by this authorSean Ong, Sean Ong orcid.org/0000-0003-1117-2409 Royal Melbourne Hospital Clinical School, University of Melbourne, Melbourne, Victoria, Australia EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Victoria, AustraliaSearch for more papers by this authorKandarpa Vasundhara, Kandarpa Vasundhara orcid.org/0000-0002-7684-8169 Department of Urology, Singapore General Hospital, Singapore, SingaporeSearch for more papers by this authorChow Kit Mun, Chow Kit Mun Department of Urology, Singapore General Hospital, Singapore, SingaporeSearch for more papers by this authorIsabella Williams, Isabella Williams orcid.org/0000-0002-4149-468X Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaSearch for more papers by this authorRavindran Kanesvaran, Ravindran Kanesvaran Division of Medical Oncology, National Cancer Centre Singapore, Singapore, SingaporeSearch for more papers by this authorJohn Yuen Shyi Peng, John Yuen Shyi Peng Department of Urology, Singapore General Hospital, Singapore, SingaporeSearch for more papers by this authorArun A. Azad, Arun A. Azad orcid.org/0000-0001-7350-5622 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, AustraliaSearch for more papers by this authorNathan Lawrentschuk, Nathan Lawrentschuk orcid.org/0000-0001-8553-5618 Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Melbourne, Victoria, Australia Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaSearch for more papers by this author First published: 27 July 2023 https://doi.org/10.1111/bju.16139Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 162: 454 2Chen K, O'Brien J, McVey A et al. Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short? Nat Rev Urol 2023; 20: 116–123 3Asim M, Tarish F, Zecchini HI et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun 2017; 8: 374 4Clarke NW, Armstrong AJ, Thiery-Vuillemin A et al. Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (Ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2023; 41(6_suppl): LBA16-LBA 5Chi KN, Rathkopf DE, Smith MR et al. Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J Clin Oncol 2022; 40(6_suppl): 12 6Rao A, Moka N, Hamstra DA, Ryan CJ. Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now? Cancers (Basel) 2022; 14: 801 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation